Aptose Biosciences Inc.
Aptose Biosciences Inc. (APTOF): 1 pipeline candidate · 1 clinical trial. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E -1.31 · 0% dilution
Lead: Phase 1
1 candidate
N/A
N/A
A transparent, data-derived signal for Aptose Biosciences Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.3M
Cash
—
Quarterly Burn
$5.8M
Runway
—
Revenue
$0
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| tuspetinib | Phase 1 |
Frequently asked questions
How many drug candidates are in Aptose Biosciences Inc.'s pipeline?
Aptose Biosciences Inc. (APTOF) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Aptose Biosciences Inc.'s lead drug candidate?
Aptose Biosciences Inc.'s most advanced tracked candidate is tuspetinib (Phase 1) for hematological malignancies.
What is Aptose Biosciences Inc.'s market capitalization?
Aptose Biosciences Inc.'s market capitalization is approximately $4.3M.
Who is the CEO of Aptose Biosciences Inc.?
Dr. William G. Rice Ph.D. is the chief executive officer of Aptose Biosciences Inc. (APTOF).
Get the full picture on Aptose Biosciences Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.